The Musella Foundation

  •  

    Patient Foundation Collaboration to Advance ONC201 in DIPG and other H3 K27M-mutant Gliomas

    Musella Foundation, Cancer Commons, xCures and Oncoceutics announced the initiation of a collaboration to develop ONC201 as a new treatment for diffuse intrinsic pontine glioma (DIPG) and other H3 K27M-mutant gliomas. Critical to the collaboration is $1M in funding from The Musella Foundation, Michael Mosier Defeat DIPG Foundation and The Cure Starts Now Foundation. Cancer Commons and xCures will contribute additional resources to the… Read more »